CD003204 (2002)
While semaglutide was originally developed for type 2 diabetes, it is effective for weight loss in non-diabetic patients
The groups tested included aCSF followed by aCSF, scopolamine (70 nM) followed by aCSF, scopolamine followed by Dihexa (300 pM), aCSF followed by Hinge (300 pM) and scopolamine + Hinge followed by Dihexa
We accept insurance, including Medicaid and Medicare, and handle prior authorization, ensuring your journey to weight loss is as smooth as possible
Anti-inflammation : The amino acids present in the injection can help to reduce skin inflammation and wrinkles, leading to a more youthful appearance
It improves blood sugar control, slows stomach emptying, and reduces appetite